Komori
Kidswell Bio (4584) · RiskWorsened

Foreign Exchange Risk Associated with Expanding Global Partnerships

First written in FY2016. 12 of 31 entries say "Materialised", first in FY2019-Q2. Latest entry: FY2026.

31entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2019-Q1MaterialisedFY2019-Q2 – FY2020MaterialisedFY2021 – FY2023WorsenedFY2024-Q3 – FY20262016: 320162017: 320172018: 420182019: 220192020: 320202021: 420212022: 420222023: 420232024: 220242025: 120252026: 12026
Same theme, other companies
Higher Outsourcing Costs from Exchange-Rate Fluctuations via Overseas VendorsA theme 12 companies write about · 12 as a headwind · 0 as a tailwind

Kidswell Bio moved to the "Worse" side of this theme in 2019.

0 other companies' latest entry also says "Worsened".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026WorsenedAnnual report

    「As sales in this business expand, payments in foreign currencies to overseas CDMOs are increasing, and the impact of foreign exchange movements on profitability is also growing.」

    The Company explains that, as the biosimilar business expands, foreign-currency payments to overseas CDMOs are increasing and the impact of foreign exchange movements on profitability is growing.
  2. FY2025WorsenedAnnual report

    「As sales of products in this business expand, payments in foreign currencies to overseas contract development and manufacturing organisations (CDMOs) are increasing, and the impact of foreign exchange movements on profitability is also growing.」

    Foreign-currency payments to overseas CDMOs are increasing, and the impact of foreign exchange movements on profitability is growing as the business expands.
  3. FY2025-H1WorsenedAnnual report

    「Meanwhile, in the biosimilar business, profit margins have declined due to inflation overseas, where the active pharmaceutical ingredients for biosimilar products are manufactured, and the depreciation of the yen.」

    Inflation at overseas manufacturing bases and the depreciation of the yen have been reflected in actual results as a decline in the biosimilar business's profit margins.
  4. FY2024-Q3WorsenedAnnual report

    「Foreign exchange loss 5,149」

    The foreign exchange loss for the cumulative third quarter was ¥5.149 million, up from ¥4.364 million in the same period of the previous fiscal year. The impact of foreign exchange movements related to overseas transactions has increased.
  5. FY2024-Q2Decrease in foreign exchange lossesAnnual report

    「Foreign exchange loss 4,813」

    The foreign exchange loss for the cumulative second quarter was ¥4.813 million, down from ¥10.553 million in the same period of the previous fiscal year. Meanwhile, the main text expresses concern about the future impact of foreign exchange movements.
  6. FY2024-Q1Decrease in foreign exchange lossesAnnual report

    「Foreign exchange loss 5,615」

    The foreign exchange loss for the cumulative first quarter was ¥5.615 million, down from ¥8.931 million in the same quarter of the previous fiscal year. The impact of foreign exchange movements related to overseas transactions continued to be reflected in actual results.
  7. FY2023WorsenedAnnual report

    「Foreign exchange loss 9,441」

    The Company recorded a foreign exchange loss of ¥9.441 million during the fiscal year, a slight increase from ¥9.366 million in the previous fiscal year.
  8. FY2023-Q3MaterialisedAnnual report

    「Foreign exchange loss 4,364」

    The Company recorded a foreign exchange loss of ¥4.364 million during the cumulative third quarter, and the impact of foreign exchange movements related to overseas transactions was reflected in actual results.
  9. FY2023-Q2MaterialisedAnnual report

    「Foreign exchange loss 10,553」

    The Company recorded a foreign exchange loss of ¥10.553 million during the cumulative second quarter, and the impact of foreign exchange movements related to overseas transactions was reflected in actual results.
  10. FY2023-Q1MaterialisedAnnual report

    「Foreign exchange loss 8,931」

    The Company recorded a foreign exchange loss of ¥8.931 million during the cumulative first quarter, and the impact of foreign exchange movements related to overseas transactions was reflected in actual results.
  11. FY2022WorsenedAnnual report

    「Foreign exchange loss 9,366」

    The foreign exchange loss for the consolidated fiscal year was ¥9.366 million, up from ¥3.028 million in the previous fiscal year. The impact of foreign exchange movements related to overseas transactions has increased.
  12. FY2022-Q3MaterialisedAnnual report

    「Foreign exchange loss 5,696」

    The Company recorded a foreign exchange loss of ¥5.696 million during the cumulative third quarter, and the impact of foreign exchange movements related to overseas transactions was reflected in actual results.
  13. FY2022-Q2MaterialisedAnnual report

    「Foreign exchange loss 2,264」

    The Company recorded a foreign exchange loss of ¥2.264 million during the cumulative second quarter, and the impact of foreign exchange movements related to overseas transactions was reflected in actual results.
  14. FY2022-Q1MaterialisedAnnual report

    「Foreign exchange loss 758」

    The Company recorded a foreign exchange loss of ¥758 thousand during the cumulative first quarter, and the impact of foreign exchange movements related to overseas transactions was reflected in actual results.
  15. FY2021MaterialisedAnnual report

    「Foreign exchange loss 3,028」

    The Company recorded a foreign exchange loss of ¥3.028 million during the consolidated fiscal year, and the impact of foreign exchange movements related to overseas transactions was reflected in actual results.
  16. FY2021-Q3Increase in Foreign Exchange GainsAnnual report

    「Foreign exchange gain 1,424」

    The Company recorded a foreign exchange gain of ¥1.424 million during the cumulative third quarter. Following the recognition of foreign exchange gains through the previous quarter, the impact of foreign exchange movements related to overseas transactions continued to be reflected in actual results.
  17. FY2021-Q1Foreign exchange gain recordedAnnual report

    「Foreign exchange gain 152」

    The Company recorded a foreign exchange gain of ¥152 thousand during the cumulative first quarter, and the impact of foreign exchange movements related to overseas transactions was reflected in actual results.
  18. FY2020MaterialisedAnnual report

    「Foreign exchange loss 1,524」

    The Company recorded a foreign exchange loss of ¥1.524 million during the consolidated fiscal year in connection with foreign exchange movements related to overseas transactions.
  19. FY2020-Q3MaterialisedAnnual report

    「Foreign exchange loss 1,402」

    The Company recorded a foreign exchange loss of ¥1.402 million during the cumulative third quarter in connection with foreign exchange movements related to overseas transactions.
  20. FY2020-Q1MaterialisedAnnual report

    「Foreign exchange loss 270」

    The Company recorded a foreign exchange loss of ¥270 thousand during the cumulative first quarter, and the impact of foreign exchange movements related to overseas transactions continued to be reflected in actual results.
  21. FY2019MaterialisedAnnual report

    「Foreign exchange loss 8,342」

    The Company recorded a foreign exchange loss of ¥8.342 million during the fiscal year in connection with foreign exchange movements related to overseas transactions.
  22. FY2019-Q2MaterialisedAnnual report

    「Foreign exchange loss 7,946」

    The Company recorded a foreign exchange loss of ¥7.946 million during the cumulative second quarter in connection with overseas transactions.
  23. FY2019-Q1RestatedAnnual report

    「During the cumulative first-quarter period, there were no new business or other risks and no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」

    The Company discloses that there have been no material changes in the foreign exchange risk associated with global partnerships.
  24. FY2018RestatedAnnual report

    「As the Company is expanding its partnerships with external parties globally, it conducts foreign-currency transactions with overseas business partners.」

    The Company continues to describe foreign-currency transactions and foreign exchange risk associated with global partnerships.
  25. FY2018-Q3RestatedAnnual report

    「During the nine months ended September, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」

    The Company discloses that there have been no material changes in the foreign exchange risk associated with global partnerships.
  26. FY2018-Q2RestatedAnnual report

    「During the six months ended June, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」

    The Company discloses that there have been no material changes in the foreign exchange risk associated with global partnerships.
  27. FY2017RestatedAnnual report

    「As the Company is expanding its partnerships with external parties globally, it conducts foreign-currency transactions with overseas business partners.」

    The Company continues to describe foreign-currency transactions and foreign exchange risk associated with the expansion of global partnerships.
  28. FY2017-Q3RestatedAnnual report

    「During the nine months ended September, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」

    The Company discloses that there have been no material changes in the foreign exchange risk associated with global partnerships.
  29. FY2017-Q2RestatedAnnual report

    「During the six months ended June, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」

    The Company discloses that there has been no new occurrence or material change in the foreign exchange risk associated with global partnerships.
  30. FY2017-Q1RestatedAnnual report

    「During the three months ended March, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」

    The Company discloses that there have been no material changes in the foreign exchange risk associated with global partnerships.
  31. FY2016First statedAnnual report

    「As the Company is expanding its partnerships with external parties globally, it conducts foreign-currency transactions with overseas business partners.」

    The Company discloses that, as it expands partnerships in Europe, North America and Asia, foreign exchange movements may affect operating results as transaction volumes and payment terms expand.
Moved together

"Equity Financing-Centered Fundraising and Dilution of Share Value" moved the same way as this thread, in the same document, in 18 of its 31 moves.

1897544★123456
  1. ★This thread
  2. 1Equity Financing-Centered Fundraising and Dilution of Share Value18×
  3. 2Financial risks from rising research and development expenses and prolonged investment recovery9×
  4. 3Concentration of Sales and Accounts Receivable Among Certain Customers7×
  5. 4Occurrence of a Loss on Order in Master Cell Bank Development5×
  6. 5Dependence on Partners and the Risks of Contract Termination and Policy Changes4×
  7. 6Focused research and development in biopharmaceuticals4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Kidswell Bio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Foreign Exchange Risk Associated with Expanding Global Partnerships | Kidswell Bio Corporation (4584) | Komori